C12N 9/224
Class 1 cas enzyme complex
Official title: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
C12N9/224 (Class 1 cas enzyme complex) appears on 245 US grants and 584 published applications in this corpus.
Search patents in C12N- Granted patents
- 245
- Published applications
- 584
- Assignees
- 181
- Inventors
- 875
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 1 | 8 |
| 2015 | 2 | 8 |
| 2016 | 1 | 9 |
| 2017 | 5 | 15 |
| 2018 | 5 | 37 |
| 2019 | 16 | 85 |
| 2020 | 20 | 38 |
| 2021 | 29 | 56 |
| 2022 | 34 | 60 |
| 2023 | 39 | 79 |
| 2024 | 32 | 82 |
| 2025 | 40 | 67 |
| 2026 | 20 | 37 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof15 Sep 2026US 12,735,471 B2iCell Gene Therapeutics Inc.
- CRISPR-associated systems and components25 Aug 2026US 12,716,060 B2Arbor Biotechnologies, Inc.
- Sequence specific degradation of single-stranded polynucleotides with CARD1 nuclease16 Jun 2026US 12,655,405 B2The Rockefeller University
- Type I-C CRISPR system from Neisseria lactamica and methods of use19 May 2026US 12,630,846 B2Cornell University
- Methods and compositions for prime editing nucleotide sequences12 May 2026US 12,624,353 B2President and Fellows of Harvard College
- Engineered type iii rna-targeting crispr effectors1 Oct 2026US 2026/0297546 A1The Regents of the University of California
- Transcriptional recording by crispr spacer acquisition from rna1 Oct 2026US 2026/0297595 A1ETH Zurich
- Control of male fertility in crops24 Sep 2026US 2026/0286380 A1University of Florida Research Foundation, Inc.
- Synthetic circuits and uses thereof17 Sep 2026US 2026/0275375 A1Strand Therapeutics Inc.
- Cas12 proteins and uses thereof27 Aug 2026US 2026/0250651 A1Guangzhou Reforgene Medicine Co., Ltd.
Most cited
By later US patents
- Engineering of systems, methods and optimized guide compositions for sequence manipulation480US 8,906,616 B2Massachusetts Institute of Technology · 2014
- Nucleic acid-guided nucleases247US 9,982,279 B1Inscripta, Inc. · 2018
- Compositions and methods directed to CRISPR/Cas genomic engineering systems118US 9,234,213 B2System Biosciences, LLC · 2016
- Methods for identifying a target site of a Cas9 nuclease110US 9,163,284 B2President and Fellows of Harvard College · 2015
- Increasing specificity for RNA-guided genome editing95US 9,885,033 B2The General Hospital Corporation · 2018